A Phase III Study to Evaluate the Efficacy and Safety of Petrelintide in Participants With Overweight or Obesity and Established Cardiovascular Disease
NCT07843472 on ClinicalTrials.gov · last registry update 2026-10-07
An unusually large phase 3: 2,500 participants, more than double the 424 typical for the stage. Due to report 28 July 2030, alongside 5 other tracked readouts that quarter. Primary outcome, as filed: Percentage Change in Body Weight from Baseline. Sponsors move these dates routinely; any movement since this site started watching is listed below. petrelintide is not approved in the US for anything yet, so this is a drug in development rather than an established treatment being extended. The registry entry has been edited 2 times since then.
- Status
- RECRUITING
- Phase
- P3
- Drug
- petrelintide
- Sponsor
- Hoffmann-La Roche
- Sponsor type
- Industry
- Enrollment
- 2,500
- Started
- 2026-09-30
- Primary completion
- 2030-07-28 estimated
Observed history
Every change this record has made since we started watching it. ClinicalTrials.gov shows only the current value. When a field is edited the previous one is overwritten and nothing is published to say so, so this history exists only because someone was recording it at the time.
| Detected | Change | Detail |
|---|---|---|
| 2026-10-07 | Status changed | NOT_YET_RECRUITING → RECRUITING |
| 2026-09-28 | First seen in registry | Registered as NOT_YET_RECRUITING, P3 |
Primary outcome
Percentage Change in Body Weight from Baseline
Conditions studied
Obesity or Overweight · Cardiovascular Disease
Every field above is taken directly from the registry record. See all detected changes across the class, or the petrelintide page for this molecule’s full trial and approval history.